PDCD1 and neoplasm: Anticancer immunity can be impaired by a variety of immunosuppressive mechanisms, including the expression of inhibitory checkpoints, such as PD-1, CTLA-4 and lymphocyte activation gene 3 (LAG3), which limit the effector function of T cells by interacting with their ligands, expressed on a wide range of tumor cells.